Roivant Sciences Ltd.
NASDAQ Global MarketTotal Valuation
Roivant Sciences Ltd. carries a market capitalization of 20.64B, placing it among publicly traded companies globally. Its enterprise value stands at 15.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 20.64B |
| Enterprise Value | 15.70B |
Share Statistics
Roivant Sciences Ltd. currently has 720.35M shares outstanding.
| Shares Outstanding | 720.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2,314.11, and the price-to-book ratio stands at -38.09.
| PE Ratio | N/A |
| PS Ratio | 2,314.11 |
| PB Ratio | -38.09 |
| P/TBV Ratio | 3.61 |
| P/FCF Ratio | -26.78 |
| P/OCF Ratio | -25.47 |
Enterprise Valuation
| EV / Sales | 1,900.15 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Roivant Sciences Ltd. maintains a current ratio of 18.37, meaning it holds 18.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 18.37 |
| Quick Ratio | 18.00 |
| Debt / Equity | 2.03 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -5.38 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -37.12 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Roivant Sciences Ltd. has paid 133.33M in income taxes, reflecting an effective tax rate of 21.66.
| Income Tax | 133.33M |
| Effective Tax Rate | 21.66 |
Stock Price Statistics
Roivant Sciences Ltd.'s stock has gained approximately 156.02141% over the past 52 weeks. The 50-day moving average sits at 28.62, while the 200-day moving average is 22.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | 156.02141% |
| 50-Day Moving Average | 28.62 |
| 200-Day Moving Average | 22.49 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Roivant Sciences Ltd. generated 8.26M in revenue and converted that into -299.77M in net income, yielding earnings per share of -0.55. EBITDA reached -1.28B, while operating income came in at -1.29B.
| Revenue | 8.26M |
| Gross Profit | 6.98M |
| Operating Income | -1.29B |
| Pretax Income | -264.58M |
| Net Income | -299.77M |
| EBITDA | -1.28B |
| EBIT | -1.29B |
| Earnings Per Share (EPS) | -0.55 |
Balance Sheet
Roivant Sciences Ltd. holds 4.29B in cash and equivalents against 107.44M in total debt, resulting in a net debt position of -1.42B. Total book value stands at -501.81M, with working capital of 4.89B providing operational flexibility.
| Cash & Cash Equivalents | 4.29B |
| Total Debt | 107.44M |
| Net Debt | -1.42B |
| Equity (Book Value) | -501.81M |
| Book Value Per Share | -0.73 |
| Working Capital | 4.89B |
Cash Flow
Roivant Sciences Ltd. produced -750.35M in operating cash flow over the past twelve months. After subtracting -8.21M in capital expenditures, free cash flow totaled -758.56M - equivalent to -1.10 per share.
| Operating Cash Flow | -750.35M |
| Capital Expenditures | -8.21M |
| Free Cash Flow | -758.56M |
| FCF Per Share | -1.10 |
Margins
Roivant Sciences Ltd. operates with a gross margin of 84.44, reflecting its pricing power and cost economics. The operating margin of -15,560.57 and net profit margin of -3,629.19 provide insight into operational efficiency.
| Gross Margin | 84.44 |
| Operating Margin | -15,560.57 |
| Pretax Margin | -3,203.12 |
| Profit Margin | -3,629.19 |
| EBITDA Margin | -15,520.04 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.70 |
| FCF Yield | -3.73 |
Scores
Roivant Sciences Ltd. posts an Altman Z-Score of 27.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 27.71 |